$1.73
1.70% today
Nasdaq, Aug 12, 07:46 pm CET
ISIN
US62818Q1040
Symbol
MBIO

Mustang Bio, Inc. Stock price

$1.76
-0.89 33.58% 1M
-1.14 39.31% 6M
-7.09 80.11% YTD
-15.59 89.86% 1Y
-551.82 99.68% 3Y
-2,300.74 99.92% 5Y
-7,348.24 99.98% 10Y
-7,348.24 99.98% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.10 6.02%
ISIN
US62818Q1040
Symbol
MBIO
Industry

Key metrics

Basic
Market capitalization
$7.7m
Enterprise Value
$-6.5m
Net debt
positive
Cash
$14.2m
Shares outstanding
3.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.9
P/B
2.1
Financial Health
Equity Ratio
-41.6%
Return on Equity
413.1%
ROCE
-299.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-10.7m | $-22.0m
EBIT
$-11.3m | $-22.0m
Net Income
$-10.7m | $-60.2m
Free Cash Flow
$-7.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
70.8% | -89.8%
EBIT
70.5% | -79.0%
Net Income
73.3% | -275.9%
Free Cash Flow
79.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-2.2
Short interest
10.5%
Employees
6
Rev per Employee
$0.0
Show more

Is Mustang Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Mustang Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mustang Bio, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Mustang Bio, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Mustang Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.92 3.92
55% 55%
-
- Research and Development Expense 3.15 3.15
89% 89%
-
-11 -11
71% 71%
-
- Depreciation and Amortization 0.57 0.57
62% 62%
-
EBIT (Operating Income) EBIT -11 -11
70% 70%
-
Net Profit -11 -11
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mustang Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mustang Bio, Inc. Stock News

Positive
Finbold
about one month ago
Shares of Mustang Bio (NASDAQ: MBIO) surged on Monday as investors responded to a significant approval from the Food and Drug Administration (FDA).
Neutral
GlobeNewsWire
about one month ago
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively
Neutral
GlobeNewsWire
5 months ago
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1).
More Mustang Bio, Inc. News

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Head office United States
CEO Manuel Litchman
Employees 6
Founded 2015
Website www.mustangbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today